March 12, 2020 / 11:45 AM / 17 days ago

BRIEF-Provention Announces Positive Data From Phase 1B Prevail Study Of PRV-3279

March 12 (Reuters) - Provention Bio Inc:

* PROVENTION ANNOUNCES POSITIVE DATA FROM PHASE 1B PREVAIL STUDY OF PRV-3279

* PROVENTION BIO INC - PRV-3279 INHIBITED FUNCTION OF B CELLS, DURABLY AND WITHOUT DEPLETION

* PROVENTION BIO INC - PRV-3279 WAS WELL TOLERATED IN HEALTHY VOLUNTEERS

* PROVENTION BIO INC - PRV-3279 WAS WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTS

* PROVENTION BIO INC - PLANS TO COMMENCE PHASE 2A PORTION OF PREVAIL STUDY IN LUPUS PATIENTS IN FIRST HALF OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below